Edition:
India

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

3,705JPY
11:16am IST
Change (% chg)

¥-45 (-1.20%)
Prev Close
¥3,750
Open
¥3,701
Day's High
¥3,719
Day's Low
¥3,676
Volume
2,405,900
Avg. Vol
6,974,079
52-wk High
¥4,943
52-wk Low
¥3,498

Latest Key Developments (Source: Significant Developments)

Skyhawk Therapeutics Announces Agreement With Takeda To Develop Novel Small Molecule Rna Splicing Modifiers
Monday, 6 May 2019 

May 6 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::SKYHAWK THERAPEUTICS ANNOUNCES AGREEMENT WITH TAKEDA TO DEVELOP NOVEL SMALL MOLECULE RNA SPLICING MODIFIERS FOR NEURODEGENERATIVE DISEASES.  Full Article

Exelixis' Partner Takeda Announces Filing Of NDA In Japan For Cabometyx For Advanced Renal Cell Carcinoma
Thursday, 25 Apr 2019 

April 25 (Reuters) - Exelixis Inc ::EXELIXIS’ PARTNER TAKEDA ANNOUNCES FILING OF NEW DRUG APPLICATION IN JAPAN FOR CABOMETYX® (CABOZANTINIB) FOR ADVANCED RENAL CELL CARCINOMA.EXELIXIS INC - REGULATORY SUBMISSION TRIGGERS $10 MILLION MILESTONE PAYMENT TO EXELIXIS UNDER COLLABORATION AND LICENSE AGREEMENT WITH TAKEDA.EXELIXIS INC - EXELIXIS WILL RECEIVE A $10 MILLION MILESTONE PAYMENT FROM TAKEDA, ANTICIPATED TO BE RECEIVED IN Q2 OF 2019.EXELIXIS INC - SUBMISSION BASED ON METEOR AND CABOSUN TRIALS AS WELL AS TAKEDA BRIDGING STUDY.  Full Article

LegoChem Biosciences, Takeda Enter into Multi-Target Research Collaboration and License Agreement
Friday, 22 Mar 2019 

March 22 (Reuters) - LegoChem Biosciences Inc <141080.KQ>::LEGOCHEM BIOSCIENCES, TAKEDA ENTER INTO MULTI-TARGET RESEARCH AND LICENSE AGREEMENT FOR DEVELOPMENT OF ANTIBODY-DRUG CONJUGATES IN IMMUNO-ONCOLOGY.TAKEDA OBTAINS RIGHTS TO LCB'S ADC PLATFORM FOR MULTIPLE TARGETS.LCB WILL RECEIVE $7.25 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS..LCB ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONE PAYMENTS OF UP TO $404 MILLION.LCB ELIGIBLE TO RECEIVE ROYALTIES ON SALES OF ANY RESULTING ADC PRODUCTS.  Full Article

Takeda And Hemoshear Therapeutics Extend Exclusive Drug Discovery Partnership In Liver Diseases
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA AND HEMOSHEAR THERAPEUTICS EXTEND EXCLUSIVE DRUG DISCOVERY PARTNERSHIP IN LIVER DISEASES.HEMOSHEAR THERAPEUTICS- HEMOSHEAR WAS ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF POTENTIALLY $470 MILLION AND ROYALTIES.HEMOSHEAR THERAPEUTICS- FURTHER ADDITIONAL FINANCIAL TERMS RELATED TO EXTENSION OF PARTNERSHIP WERE NOT DISCLOSED.  Full Article

Takeda Receives U.S. FDA Approval To Manufacture Flexbumin At New Plasma Manufacturing Facility
Monday, 18 Mar 2019 

March 18 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA RECEIVES U.S. FDA APPROVAL TO MANUFACTURE FLEXBUMIN® AT NEW PLASMA MANUFACTURING FACILITY NEAR COVINGTON, GEORGIA.TAKEDA PHARMACEUTICAL - FDA APPROVED SECOND SUBMISSION FOR ITS NEW PLASMA MANUFACTURING FACILITY FOR PRODUCTION OF FLEXBUMIN 25% USP, 25% SOLUTION.  Full Article

Infinity Pharmaceuticals Announces Royalty Monetization Of COPIKTRA For $30 Mln Gross Proceeds
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS ANNOUNCES ROYALTY MONETIZATION OF COPIKTRA FOR $30 MILLION GROSS PROCEEDS.INFINITY PHARMACEUTICALS INC - ANNOUNCED ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS (HCR) FOR RIGHT TO RECEIVE CERTAIN ROYALTY PAYMENTS.INFINITY PHARMACEUTICALS INC - ROYALTY PAYMENTS BASED ON WORLDWIDE ANNUAL NET SALES OF COPIKTRA (DUVELISIB), PAYABLE BY VERASTEM.INFINITY PHARMACEUTICALS - UNDER AGREEMENT, HCR HAS AGREED TO PAY CO A $30 MILLION UPFRONT PAYMENT AND UP TO $20 MILLION IN POTENTIAL MILESTONE PAYMENTS.INFINITY PHARMACEUTICALS INC - IN CONNECTION WITH ROYALTY MONETIZATION, INFINITY ENTERED INTO AN AMENDMENT OF ITS LICENSE AGREEMENT WITH TAKEDA.INFINITY PHARMACEUTICALS - AS PER AMENDMENT OF LICENSE AGREEMENT WITH TAKEDA, TAKEDA HAS AGREED TO RECEIVE A PORTION OF TOTAL INVESTMENT AMOUNT.  Full Article

Takeda's Global Acquisition Of Shire Creates An Expanded Takeda Canada
Thursday, 10 Jan 2019 

Jan 10 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA'S GLOBAL ACQUISITION OF SHIRE CREATES AN EXPANDED TAKEDA CANADA TO BRING BETTER HEALTH AND A BRIGHTER FUTURE TO CANADIANS.  Full Article

Shire Says Following Court Order, Scheme Has Now Become Effective
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Shire Plc::SHIRE PLC - FOLLOWING COURT ORDER , SCHEME HAS NOW BECOME EFFECTIVE, ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF SHIRE IS NOW OWNED BY TAKEDA.  Full Article

Takeda - Notice Regarding Amounts Of Capital And Capital Reserves To Be Increased By Issuance Of New Shares In Connection With Shire Acquisition
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::NOTICE REGARDING AMOUNTS OF CAPITAL AND CAPITAL RESERVES TO BE INCREASED BY ISSUANCE OF NEW SHARES IN CONNECTION WITH SHIRE ACQUISITION.AMOUNTS OF BOTH STATED CAPITAL AND CAPITAL RESERVES TO BE INCREASED BY ABOUT 1.565 TRLN YEN EACH.  Full Article

Takeda Says It Now Owns Entire Issued And To Be Issued Share Capital Of Shire
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd <4502.T>::NOTICE REGARDING THE ACQUISITION OF THE ENTIRE ISSUED AND TO BE ISSUED SHARE OF SHIRE.CONFIRMS SCHEME OF ARRANGEMENT IN RELATION TO PROPOSED ACQUISITION OF SHIRE BECAME EFFECTIVE JAN 8.ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF SHIRE IS NOW OWNED BY TAKEDA.  Full Article

Photo

Takeda scraps late-stage amyloidosis study

Takeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a late-stage study testing its experimental treatment for amyloidosis, as it did not meet the first of two main goals.